189 related articles for article (PubMed ID: 34257274)
1. Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.
Ritter V; Krautter F; Klein D; Jendrossek V; Rudner J
Cell Death Dis; 2021 Jul; 12(7):694. PubMed ID: 34257274
[TBL] [Abstract][Full Text] [Related]
2. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
3. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells.
Wang B; Ni Z; Dai X; Qin L; Li X; Xu L; Lian J; He F
Mol Cancer; 2014 Apr; 13():98. PubMed ID: 24779770
[TBL] [Abstract][Full Text] [Related]
4. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun SY; Ramalingam SS; Khuri FR; Curran WJ; Deng X
Cancer Res; 2013 Sep; 73(17):5485-96. PubMed ID: 23824742
[TBL] [Abstract][Full Text] [Related]
5. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL.
Li JY; Li YY; Jin W; Yang Q; Shao ZM; Tian XS
J Exp Clin Cancer Res; 2012 Dec; 31(1):102. PubMed ID: 23259599
[TBL] [Abstract][Full Text] [Related]
6. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
7. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
8. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.
Loriot Y; Mordant P; Dugue D; Geneste O; Gombos A; Opolon P; Guegan J; Perfettini JL; Pierre A; Berthier LK; Kroemer G; Soria JC; Depil S; Deutsch E
Cell Death Dis; 2014 Sep; 5(9):e1423. PubMed ID: 25232677
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
Lu Y; Bian D; Zhang X; Zhang H; Zhu Z
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
[TBL] [Abstract][Full Text] [Related]
11. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
[TBL] [Abstract][Full Text] [Related]
12. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
Jin J; Xiong Y; Cen B
Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
[TBL] [Abstract][Full Text] [Related]
14. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
[TBL] [Abstract][Full Text] [Related]
15. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
16. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of BCL-2/X
Zoeller JJ; Vagodny A; Taneja K; Tan BY; O'Brien N; Slamon DJ; Sampath D; Leverson JD; Bronson RT; Dillon DA; Brugge JS
Mol Cancer Ther; 2019 Jun; 18(6):1115-1126. PubMed ID: 30962322
[TBL] [Abstract][Full Text] [Related]
18. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.
Kim KW; Moretti L; Mitchell LR; Jung DK; Lu B
Clin Cancer Res; 2009 Oct; 15(19):6096-105. PubMed ID: 19773376
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
